UBS Maintains Buy on Adient, Raises Price Target to $33

Benzinga Newsdesk www.benzinga.com Positive 77.6%

Neg 0% Neu 0% Pos 77.6%

UBS analyst Joseph Spak maintains Adient (NYSE:ADNT) with a Buy and raises the price target from $32 to $33.

Comments

No comments yet. Be the first!